Sotorasib Versus Docetaxel for Previously Treated Patients With KRASG12C Mutated NSCLC: Data From CodeBreaK 200

Opinion
Video

Dr Narjust Florez discusses the higher incidence of hepatotoxicity with sotorasib as shown in real-world data, and suggests adagrasib as a preferable option for patients with pre-existing liver dysfunction or inflammation, highlighting the need to consider patient history and liver function when choosing KRAS inhibitors.

Recent Videos
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
The observed safety profile of HA121-28 was similar to that of other multi-targeted RET tyrosine kinase inhibitors.

HA121-28 Shows Promising Efficacy in Advanced RET Fusion+ NSCLC

Roman Fabbricatore
March 5th 2025
Article

The observed safety profile of HA121-28 was similar to that of other multi-targeted RET tyrosine kinase inhibitors.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Real-World Efficacy Greater Than Trial Data For Dacomitinib in EGFR+ NSCLC

Real-World Efficacy Greater Than Trial Data For Dacomitinib in EGFR+ NSCLC

Tim Cortese
February 27th 2025
Article

The survival benefit of dacomitinib was improved in real-world settings for patients with EGFR-mutant NSCLC compared with what the ARCHER 1050 trial shows.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Treatment with mobocertinib produces clinically meaningful delays in time to deterioration among patients enrolled on the phase 3 EXCLAIM-2 trial.

Mobocertinib Does Not Improve PFS Vs Chemotherapy in EGFR Exon 20+ NSCLC

Russ Conroy
February 25th 2025
Article

Treatment with mobocertinib produces clinically meaningful delays in time to deterioration among patients enrolled on the phase 3 EXCLAIM-2 trial.

Neoadjuvant Nivolumab/Chemo Improves OS Vs Chemotherapy in Resectable NSCLC

Neoadjuvant Nivolumab/Chemo Improves OS Vs Chemotherapy in Resectable NSCLC

Tim Cortese
February 19th 2025
Article

Updated, comprehensive OS results with the combination in resectable NSCLC will be shared in a future peer-reviewed setting.